4,901 trials
HIV Infections
Primary: Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval at Steady State (AUC[0-tau]) of GSK3640254 — 27.03; 30.70…
Healthy Volunteer
Primary: Part A: PF-06882961 Maximum Observed Concentration (Cmax) — 15.69; 17.09 nanogram per milliliter (ng/mL)
Asthma
Primary: Percentage of Patients With Treatment-emergent Adverse Events Related to BI 894416 — 0; 28.6; 37.5; 62.5 Percentage of participants
Advanced Melanoma · Non-small Cell Lung Cancer · Renal Cell Carcinoma
Primary: Safety and Tolerability Measured by Assessing Serious Adverse Events (SAEs)and Adverse Events (AEs) — 1; 3; 2; 2 Participants
Healthy Volunteers
Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 5.6; 0.0; 16.7; 0.0 Percentage of participants
Healthy
Primary: Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 9077.08; 951.58 hour * nanomole / liter
Healthy
Primary: Placebo-corrected Change From Baseline For QTcF (ΔΔQTcF) for ALXN1840 Using The By-time Point Analysis — -0.21; -0.31; 0.07; -0.64 ms
Healthy Participants
Primary: Maximum Observed Plasma Concentration (Cmax) of Rosuvastatin — 3.80; 6.47 ng/mL
Healthy
Primary: Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 371.77; 526.50 Nanomole*hour…
Healthy
Primary: Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 4436.69; 4458.63 nanomole…
Healthy
Primary: Number of Participants With Investigator Defined Drug-related Adverse Events — 2; 1; 4; 2 Participants
Healthy
Primary: Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification…
Healthy
Primary: Area Under the Concentration-time Curve of Spesolimap in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 3380; 6960; 10300; 1580 Day times…
Non-squamous Non-small-cell Lung Cancer · Anlotinib
Primary: the Maximum Tolerated Dose (MTD) — 10 mg
RSV Infection
Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade - (RSV-seropositive Participants) — 8; 5; 0; 0 Participants